Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8TF50
UPID:
ZN526_HUMAN
Alternative names:
-
Alternative UPACC:
Q8TF50; B3KV29; Q69YI2; Q96E24
Background:
Zinc finger protein 526, encoded by the gene with accession number Q8TF50, plays a crucial role in transcriptional regulation. Its structure, characterized by zinc finger motifs, suggests a significant function in DNA binding and gene expression modulation.
Therapeutic significance:
Linked to Dentici-Novelli neurodevelopmental syndrome, a disorder marked by developmental delays and intellectual challenges, understanding Zinc finger protein 526's role could unveil new therapeutic avenues. Its involvement in gene regulation makes it a potential target for gene therapy strategies aimed at mitigating disease symptoms.